All In Biotech

Drug Trial Radar · NCT04620213

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Randomized, Parallel Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 185 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

185

Actual

Start

Nov 18, 2020

Primary completion

Dec 23, 2020

Study completion Mar 15, 2021

Sponsor

Lead sponsor
Opus Genetics, IncIndustry
Sponsor type
Industry
First posted
Nov 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objectives of this study are: * To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine * To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd) * To evaluate the safety of Nyxol * To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis

Conditions

  • Mydriasis
  • Dilation

Interventions

  • Phentolamine Ophthalmic Solution 0.75%Drug

    0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

  • Phentolamine Ophthalmic Solution Vehicle (Placebo)Other

    Topical sterile ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Subjects' Study Eyes With Pupil Diameter Returning to BaselineTime frame: 90 minutes

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site 11

    Newport Beach, California

  • Clinical Site 10

    San Diego, California

  • Clinical Site 9

    Longwood, Florida

  • Clinical Site 6

    Orlando, Florida

  • Clinical Site 2

    Roswell, Georgia

  • Clinical Site 7

    Pittsburg, Kansas

  • Clinical Site 3

    Shawnee Mission, Kansas

  • Clinical Site 5

    Athens, Ohio

  • Clinical Site 12

    Cincinnati, Ohio

  • Clinical Site 1

    Cleveland, Ohio

  • Clinical Site 8

    Warwick, Rhode Island

  • Clinical Site 4

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.